J Clin Outcomes Manage
Sumatriptan/Naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials
Taylor FR, Heiring JO, Messina E, Braverman-Panza J, Ames MH, Byrd SC, McDonald SA, Burch SP
Abstract Objective: To examine the effects of early intervention with sumatriptan/naproxen sodium for migraine on functional ability, productivity, and patient satisfaction. Design: 2 randomized, double-blind, parallel-group studies. Participants and setting: Migraineurs aged 18 to 65 years at 106 U.S. neurology and headache clinics treated with sumatriptan 85 mg formulated with RT technology/naproxen sodium 500 mg or placebo within 1 hour of pain onset. Measurements: Functional ability on a 5-point scale through 4 hours postdose, migraine-associated disability time through 24 hours postdose, and satisfaction on the Revised Patient Perception of Migraine Questionnaire (PPMQ-R). Results: Two and 4 hours postdose, approximately twice as many patients reported normal functional ability with sumatriptan/naproxen than placebo in each study (P < 0.001). Total disability time was 47% to 48% lower with sumatriptan/naproxen than placebo (2.7 versus 5.1 hours study 1; 2.7 versus 5.2 hours study 2; P < 0.001). Mean lost workplace productivity and lost nonworkplace activity time were lower with sumatriptan/naproxen than placebo (lost workplace productivity: 1.8 versus 3.1 hours study 1 [P < 0.001]; 1.7 versus 2.5 hours study 2 [P < 0.05]; lost nonworkplace activity time: 2.2 versus 4.1 hours study 1; 2.2 versus 4.3 hours study 2 [P < 0.001]). Mean satisfaction scores were significantly higher with sumatriptan/naproxen versus placebo for the efficacy, functionality, and ease of use subscales and the total score in both studies. Conclusion: Sumatriptan/naproxen confers rapid, restoration of functional ability and productivity in migraine and receives high patient satisfaction ratings.
Search the Turner White index to find abstracts of articles published in JCOM.